Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2003

View Archived Issues

Favorable effects on bone disease reported for lanthanum carbonate in hemodialysis

Lysostaphin cream as an alternative treatment for S. aureus infection

Etanercept does not increase the rate of malignancies in rheumatoid arthritis

PI3-kinase modulators with antiproliferative activity reported by Iconix

New antiinflammatory glucocorticoids in early development at GSK

Preparation and use of new GSK-3 inhibitors claimed by Servier

U. of Connecticut researchers identify novel cannabinoid agonists for pain and other uses

Pfizer claims new 5-HT4 receptor agonists with utility in gastrointestinal disorders

Scientists at Ortho-McNeil prepare dual inhibitors of cathepsin G and chymase

Novel antibacterial oxazolidinones prepared and tested by AstraZeneca researchers

New tissue-selective androgen receptor modulators discovered at Merck

Paladin licenses Visicol from InKine

MediGene completes enrollment in European part of phase III Polyphenon E trial

CytRx obtains license for DNA-based HIV vaccine

Data safety monitoring board clears phase III Thymitaq trial to continue

FDA approves Gleevec for Ph+ CML

Vertex reviews internal and partnered progress

Triapine in new phase II trial with gemcitabine for NSCLC

GW and Bayer enter marketing agreement for Sativex

GSK and Medivir sign licensing agreement for MIV-210

New immunosuppressive compound under development at Isotechnika

Extended-release alprazolam set for June launch

Phase II trial planned for GTI-2501 in metastatic prostate cancer

WX-UK1 cleared for phase I trials in the U.S.

CollaGenex signs agreement with EpiTan to develop topical formulation of Melanotan

Roche and Maxygen form interferon development alliance

First European country approves Fuzeon

Selectin inhibitor shows potential in the management of uveitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...